# Air Force Selects Cresilon for SBIR Evaluation

The Department of the Air Force selected Cresilon through AFWERX for a Phase I Small Business Innovation Research (SBIR) contract to evaluate TRAUMAGEL, a hemostatic device for controlling hemorrhage when military personnel may not have immediate medical support. The project start was stated as June 22, 2026, and the selection was announced October 26, 2026. The signals provide no contract value or number, and describe technology evaluation—not an operational purchase or confirmed follow-on award.

- The award is an early-stage defense medical technology development opportunity; any fielding or follow-on procurement depends on the evaluation’s outcome.
- Medical technology firms and potential teammates can use the selection as an indication of Air Force interest in hemorrhage-control capabilities for austere operational settings, while distinguishing SBIR development activity from a production opportunity.
- Procurement and business-development teams should treat the disclosed scope as a Phase I evaluation; the signals do not identify a contract value, solicitation number, or subsequent procurement timeline.

**Jurisdictions:** federal
**Industries:** Defense & Military, Healthcare
**Topics:** Grants & Funding
**Published:** October 26, 2026

### Government Entities
- Department of the Air Force (DAF)
- AFWERX (AFWERX)
- Air Force Research Laboratory (AFRL)

### Vendors
- Cresilon Inc. (SBIR awardee)

### Sources
- [U.S. Air Force Selects Cresilon's TRAUMAGEL Through AFWERX SBIR Program to Advance Hemorrhage Control for Military Use](https://finance.yahoo.com/healthcare/articles/u-air-force-selects-cresilons-122000060.html) - Yahoo Finance
- [U.S. Air Force Selects Cresilon's TRAUMAGEL Through AFWERX SBIR Program to Advance Hemorrhage Control for Military Use](https://www.prnewswire.com/news-releases/us-air-force-selects-cresilons-traumagel-through-afwerx-sbir-program-to-advance-hemorrhage-control-for-military-use-302918775.html) - PR Newswire